Fox News contributor Dr. Marc Siegel joins'Fox News Live' to discuss the FDA approving a new Alzheimer treatment drug and the FDA banning bromide vegetable oils. New details have emerged about how Alzheimer's disease affects the brain. Researchers led by the Allen Institute for Brain Science in Seattle and University of Washington Medicine have identified cellular changes in the brains of people with the disease -- and a timeline of when they occur. "Instead of looking at AD just through the usual lens of plaques and tangles, we focused on how specific cell types were changed in each phase," study author Dr. Kyle Travaglini, Ph.D., a scientist at Allen Institute, told Fox News Digital via email. ALZHEIMER'S DISEASE COULD BE SLOWED BY BOOSTING A CERTAIN PROTEIN IN THE BRAIN, RESEARCHERS SAY "We identified two main phases in AD by arranging donors along a continuous disease trajectory -- a slow, early phase with low levels of pathology and no cognitive decline, followed by a later phase where there's a huge buildup of pathology and cognitive decline."

Two Ohio patients who participated in the trials spoke to Fox News Digital about how Leqembi has impacted their Alzheimer's journeys. On the left, patient Joan Murtaugh is pictured with her husband Larry Murtaugh; on right, John Domeck is shown with his wife Ann Domeck. 'NEW HOPE' – Two Ohio patients share how the new Alzheimer's drug has kept them "fully functional." EYE ON BRAIN HEALTH – Vision problems could point to dementia risk, study finds. HIGH-TECH HEALTH – Here's how a new app is helping seniors stay on top of their prescriptions and vitals.

Alzheimer's disease is becoming increasingly prevalent as life expectancies lengthen. But the complexity of the condition makes it hard to find effective treatments. One way to expedite the search that's yielded promising results is using AI to find existing drugs that could be repurposed to combat the disorder. Harvard researchers recently used the approach to identify 80 candidate medications that merit further investigation. They discovered the contenders through a framework they call DRIAD (Drug Repurposing In Alzheimer's Disease).